• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study.

作者信息

Georgakopoulos Jorge R, Felfeli Tina, Drucker Aaron M, Jo Christine E, Piguet Vincent, Yeung Jensen

机构信息

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.

出版信息

JAAD Int. 2021 Jul 31;4:67-69. doi: 10.1016/j.jdin.2021.06.001. eCollection 2021 Sep.

DOI:10.1016/j.jdin.2021.06.001
PMID:34409396
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8362263/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f62c/8362263/224f8560298c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f62c/8362263/224f8560298c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f62c/8362263/224f8560298c/gr1.jpg

相似文献

1
Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study.度普利尤单抗治疗特应性皮炎的两年疗效、安全性及药物留存率：一项加拿大多中心真实世界回顾性研究
JAAD Int. 2021 Jul 31;4:67-69. doi: 10.1016/j.jdin.2021.06.001. eCollection 2021 Sep.
2
Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.真实世界中评估度普利尤单抗疗效和不良事件风险的证据：一项系统评价和荟萃分析。
J Am Acad Dermatol. 2021 Jan;84(1):139-147. doi: 10.1016/j.jaad.2020.08.051. Epub 2020 Aug 18.
3
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.度普利尤单抗联合外用皮质类固醇治疗中重度特应性皮炎的长期管理（LIBERTY AD CHRONOS）：一项为期 1 年、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.
4
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.度普利尤单抗治疗真实世界中法国多中心成人队列特应性皮炎的疗效和安全性。
J Am Acad Dermatol. 2019 Jul;81(1):143-151. doi: 10.1016/j.jaad.2019.02.053. Epub 2019 Feb 27.
5
Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.真实世界中成人特应性皮炎患者接受度普利尤单抗治疗的经验：患者病历的回顾性分析。
Int J Dermatol. 2020 Feb;59(2):253-256. doi: 10.1111/ijd.14573. Epub 2019 Jul 8.
6
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.度普利尤单抗治疗外用药物治疗控制不佳的中重度特应性皮炎成人患者的疗效和安全性：一项随机、安慰剂对照、剂量范围的 2b 期临床试验。
Lancet. 2016 Jan 2;387(10013):40-52. doi: 10.1016/S0140-6736(15)00388-8. Epub 2015 Oct 8.
7
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供长达 3 年的良好安全性和持续疗效。
Am J Clin Dermatol. 2020 Aug;21(4):567-577. doi: 10.1007/s40257-020-00527-x.
8
Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice.韩国度普利尤单抗治疗中重度特应性皮炎的回顾性研究：度普利尤单抗在实际临床应用中的疗效与安全性
J Clin Med. 2020 Jun 24;9(6):1982. doi: 10.3390/jcm9061982.
9
Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective review.地氯雷他定在特应性皮炎患儿中的超适应证使用：一项多中心回顾性研究。
J Am Acad Dermatol. 2020 Feb;82(2):407-411. doi: 10.1016/j.jaad.2019.10.010. Epub 2019 Oct 10.
10
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).度普利尤单抗联合外用皮质类固醇治疗对环孢素 A 应答不足或不耐受或当这种治疗在医学上不建议时的中重度特应性皮炎成人患者：一项安慰剂对照、随机 III 期临床试验（LIBERTY AD CAFÉ）。
Br J Dermatol. 2018 May;178(5):1083-1101. doi: 10.1111/bjd.16156. Epub 2018 Mar 25.

引用本文的文献

1
Drug Survival, Retention, and Persistence of Dupilumab in Adults and Adolescents with Atopic Dermatitis: A Narrative Literature Review.度普利尤单抗在成人和青少年特应性皮炎患者中的药物生存、留存及持续性：一项叙述性文献综述
Adv Ther. 2025 Jan;42(1):94-105. doi: 10.1007/s12325-024-03052-z. Epub 2024 Nov 15.
2
Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis.度普利尤单抗、甲氨蝶呤和环孢素A在儿童特应性皮炎中的药物留存率
JAMA Dermatol. 2025 Jan 1;161(1):12-21. doi: 10.1001/jamadermatol.2024.3717.
3
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study.

本文引用的文献

1
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供长达 3 年的良好安全性和持续疗效。
Am J Clin Dermatol. 2020 Aug;21(4):567-577. doi: 10.1007/s40257-020-00527-x.
2
Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.度普利尤单抗治疗特应性皮炎患者的长期疗效和安全性：荷兰特应性皮炎治疗登记研究（TREAT NL）的结果。
J Am Acad Dermatol. 2020 Nov;83(5):1375-1384. doi: 10.1016/j.jaad.2020.05.128. Epub 2020 May 30.
3
度普利尤单抗治疗特应性皮炎患者的长期疗效：RELIEVE-AD研究3年随访结果
Dermatol Ther (Heidelb). 2023 Sep;13(9):2107-2120. doi: 10.1007/s13555-023-00965-5. Epub 2023 Aug 8.
4
Characterising the chronicity of dupilumab-associated ocular surface disease: an analysis of a retrospective case series.描述度普利尤单抗相关眼表疾病的慢性特征：一项回顾性病例系列分析。
BMJ Open Ophthalmol. 2022 May;7(1). doi: 10.1136/bmjophth-2021-000947.
5
Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset.度普利尤单抗在特应性皮炎患者中的真实世界有效性：电子病历数据集分析
Dermatol Ther (Heidelb). 2022 Jun;12(6):1337-1350. doi: 10.1007/s13555-022-00731-z. Epub 2022 May 11.
Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study.
临床实践中评估度普利尤单抗治疗中度至重度特应性皮炎的长期疗效、安全性及停药原因：一项回顾性队列研究
J Am Acad Dermatol. 2020 Jun;82(6):1530-1532. doi: 10.1016/j.jaad.2020.02.029. Epub 2020 Feb 16.
4
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.度普利尤单抗在接受 3 期开放标签扩展研究的中重度特应性皮炎患者中显示出长期安全性和疗效。
J Am Acad Dermatol. 2020 Feb;82(2):377-388. doi: 10.1016/j.jaad.2019.07.074. Epub 2019 Jul 30.